Fresenius Medical Care AG & Co. KGaA
NYSE:FMSMedical - Care Facilities
-$0.18 today
- Market cap
- $11.26B
- Beta
- 0.81
- P/E (TTM)
- 11.9
- EPS (TTM)
- $3.43
- Dividend yield
- 3.65%
Volume 1.92M
Average 0.72M
FMS EBITDA Margin
EBITDA as a percentage of revenue.
Fresenius Medical Care AG & Co. KGaANYSE: FMS
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin holds steady near 17.1%
EBITDA Margin was 17.1% in Q2 FY2026, down 0.1 pp from a year earlier. On a trailing-twelve-month basis it was 17.6%, up 1.4 pp year over year. Over 3 fiscal years it narrowed by 0.3 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 9 analysts of 16.7% for the fiscal year ending Dec 2026, down from 17.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 17.1%+0.5 pp QoQ
- Last fiscal yearDec 2025
- 17.3%+0.7 pp YoY
- LTMJun 2026
- 17.6%+1.4 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -0.1 pp | -0.5 pp | -0.4 pp |
| 1 year | +0.7 pp | -0.6 pp | -1.3 pp |
| 3 years | -0.3 pp | -1.7 pp | -1.4 pp |
| 5 years | -0.7 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 17.3%
- Year-over-year change
- +0.7pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.3% | +0.7pp |
| FY2024 | 2024-12-31 | 16.6% | +0.1pp |
| FY2023 | 2023-12-31 | 16.5% | -1.1pp |
| FY2022 | 2022-12-31 | 17.6% | -2.5pp |
| FY2021 | 2021-12-31 | 20.1% | — |
EBITDA Margin vs competitors
How FMS compares with its peers on the latest reported figures
- FMS's LTM Jun 2026 EBITDA Margin of 17.6% is the 2nd highest of the 4 companies compared; the peer median is -2.5%.
- Its year-over-year change of +1.4 pp is the highest of 4, against a peer median of -5.1 pp.
- Over three fiscal years its change of -0.3 pp compares with a peer median of +8.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 19.7% | -0.9 pp | +1.7 pp | |
| LTM Jun 2026 | 17.6% | +1.4 pp | -0.3 pp | |
| LTM Mar 2026 | -2.5% | -5.1 pp | +8.2 pp | |
| LTM Sep 2026 | -16.4% | -11.2 pp | +278.1 pp | |
| Peer median (excluding FMS) | -2.5% | -5.1 pp | +8.2 pp | |
Competitors are the stored peer set for FMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 17.62B | 19.4B | 19.45B | 19.34B | 19.63B |
| Cost of Revenue | 12.85B | 14.5B | 14.53B | 14.58B | 14.6B |
| Gross Profit | 4.77B | 4.89B | 4.93B | 4.76B | 5.03B |
| Gross Margin | 27.1% | 25.2% | 25.3% | 24.6% | 25.6% |
| Research & Development | 220.78M | 228.62M | 231.97M | 183.49M | 157.98M |
| Selling, General & Admin | 2.77B | 3.17B | 3.2B | 3.14B | 3.03B |
| Operating Expenses | 2.92B | 3.38B | 3.56B | 3.29B | 3.2B |
| Depreciation & Amortization | 1.62B | 1.84B | 1.75B | 1.74B | 1.5B |
| EBITDA | 3.55B | 3.42B | 3.21B | 3.21B | 3.4B |
| EBITDA Margin | 20.1% | 17.6% | 16.5% | 16.6% | 17.3% |
| Operating Income | 1.85B | 1.51B | 1.37B | 1.47B | 1.83B |
| Operating Margin | 10.5% | 7.8% | 7.0% | 7.6% | 9.3% |
| Interest Income | 73.17M | 67.66M | 88.22M | 71.58M | 69.61M |
| Interest Expense | 353.6M | 360.14M | 424.64M | 407.04M | 384.41M |
| Other Income / Expenses | (280.43M) | (292.48M) | (336.42M) | (410.45M) | (314.59M) |
| Income Before Tax | 1.57B | 1.22B | 1.03B | 1.06B | 1.51B |
| Pre-Tax Margin | 8.9% | 6.3% | 5.3% | 5.5% | 7.7% |
| Income Tax Expense | 352.83M | 324.95M | 300.56M | 316.06M | 320.97M |
| Net Income | 969.31M | 673.41M | 499M | 537.91M | 978.37M |
| Net Margin | 5.5% | 3.5% | 2.6% | 2.8% | 5.0% |
| EPS (Basic) | 0.83 | 0.57 | 0.85 | 0.92 | 1.68 |
| EPS (Diluted) | 0.83 | 0.57 | 0.85 | 0.92 | 1.68 |
| Weighted Avg Shares | 1.17B | 1.17B | 586.83M | 586.83M | 582.38M |
| Weighted Avg Shares (Diluted) | 1.17B | 1.17B | 586.83M | 586.83M | 582.38M |
Fresenius Medical Care AG & Co. KGaA
NYSE:FMS
Intrinsic Alpha fair value
Locked
Current Price
$20.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.